EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?

Figures & data

Table 1 Demographic and other baseline characteristics

Characteristics	Findings
Median age, years	59 years (range: 37–80)
Sex
Male, n	22
Female, n	7
Smokers, n	10/29* (34.4%)
EGFR mutation, n
Exon 19	15 (51.7%)
Exon 20	1 (3.4%)
Exon 21	13 (44.8%)
TKI therapy at some point during treatment	19/29 (65.5%)
TKI as first-line therapy	7/29 (24.1%)
ECOG–PS score
0	2
1	10
2	10
>2	4
Data not available	3

Notes: EGFR mutation-positive SCC of the lung: n=29.

* Details of smoking history were available in only 24 out of the 29 patients.

Abbreviations: ECOG-PS, Eastern Cooperative Oncology Group–Performance Scale; SCC, squamous cell carcinoma; TKI, tyrosine kinase inhibitor.

Table 2 Response rate for TKI therapy

Response to TKI	% (n)
CR	0
PR	26.3 (5/19)
SD	21 (4/19)
PD	15.8 (3/19)
CBR (CR + PR + SD at 4 months)	47.3 (9/19)
Data not available*	36.8 (7/19)

Note:

* Considered as progression for analysis purpose.

Abbreviations: CBR, clinical benefit rate; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor.

Figure 1 Progression-free survival (PFS) of whole cohort.

Figure 2 Overall survival for patients who had taken TKI versus those who had not been given TKI therapy.

Abbreviations: CI, confidence interval; HR, hazard ratio; TKI, tyrosine kinase inhibitor.

Table 3 Multivariate analysis for factors affecting overall survival

Variable	P-value	HR	95% CI for HR
			Lower	Upper
Age <60 years	0.950	1.002	0.955	1.051
Exon 19 mutation	0.024	0.226	0.062	0.820
Smoking history	0.013	4.994	1.407	17.720
ECOG-PS >1	0.001	17.775	3.054	103.466
Treatment with a TKI	0.000	0.036	0.007	0.193

Abbreviations: CI, confidence interval; ECOG-PS, Eastern Cooperative Oncology Group–Performance Scale; HR, hazard ratio; TKI, tyrosine kinase inhibitor.